Acurx Pharmaceuticals (ACXP) Income towards Parent Company (2024 - 2026)

Acurx Pharmaceuticals (ACXP) has 3 years of Income towards Parent Company data on file, last reported at -$1.7 million in Q1 2026.

• Quarterly Income towards Parent Company rose 21.79% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.5 million (up 37.66% YoY) and the FY2025 annual result came in at -$8.0 million, up 44.12% from the prior year.
• Income towards Parent Company slipped to -$1.7 million in Q1 2026, from -$1.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$1.6 million in Q4 2025 to a low of -$4.1 million in Q2 2024.
• A 3-year average of -$2.4 million and a median of -$2.2 million in 2025 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2025 — Income towards Parent Company soared 46.25% — and 2026, when it increased 21.79%.
• Tracing ACXP's Income towards Parent Company over 3 years: stood at -$2.9 million in 2024, then surged by 46.25% to -$1.6 million in 2025, then slipped by 6.51% to -$1.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$1.7 million (Q1 2026), -$1.6 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.